Bonesupport Holding AB
Research Bonesupport Holding AB (BONEX) on Bullrun: valuation model: 24.1% overvalued, market cap SEK 13.78B, P/E 75.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBONEX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencySEK
- Valuation signal24.1% overvalued
- Market capSEK 13.78B
- P/E75.5
- Financial periodFY2024
- RevenueSEK 898.73M
- Revenue growth52.0%
- Net incomeSEK 133.75M
- Free cash flowSEK 64.23M
- Gross margin92.6%
Valuation Snapshot
Bullrun's latest valuation model marks Bonesupport Holding AB as 24.1% overvalued; latest market cap is SEK 13.78B; P/E is 75.5.
About Bonesupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection;
Frequently asked questions
Is Bonesupport Holding AB overvalued or undervalued?
Bullrun's valuation model currently marks Bonesupport Holding AB as 24.1% overvalued.
What is Bonesupport Holding AB's market cap?
Bonesupport Holding AB's market capitalization is SEK 13.78B.
What is Bonesupport Holding AB's P/E ratio?
Bonesupport Holding AB's price-to-earnings (P/E) ratio is 75.5.
What does Bonesupport Holding AB do?
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone;